ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IDYA vs VRDN // EV/EBITDA & P/E VALUATION

IDEAYA Biosciences Inc. (NASDAQ) VS. Viridian Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: IDYA 4 — VRDN 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IDYA VS. VRDN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IDYA VRDN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -13.80% -35.00% +21.20 IDYA /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -2.31% -9.85% +7.54 IDYA /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -52.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 21.49 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 IDYA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 35.6 71.8 -36.20 VRDN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.05B $2.87B $186.6M IDYA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IDYA REV VRDN REV IDYA GROSS % VRDN GROSS % IDYA FCF VRDN FCF
FY 2025 $218.7M $1.02B — — -$73.5M -$276.9M
FY 2024 $7.0M $837.3M — — -$251.4M -$232.8M
FY 2023 $23.4M $712.5M — — -$115.2M -$184.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IDYA // BETA —
VRDN // BETA —